Develops cell therapies for various indications.
Jun 2026Revenue $13.1M/yrExpenses $39.9M/yr
No trendCash runway ≈ 2.1 years from Jun 2026
Figures by year
When will Lineage Cell Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $13.1M and expenses $39.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $14.6M | $51.2M | −$36.6M |
| Dec 2024 | $9.50M | $31.0M | −$21.5M |
| Dec 2023 | $8.95M | $33.7M | −$24.7M |
| Dec 2022 | $14.7M | $37.2M | −$22.5M |
| Dec 2021 | $4.34M | $53.6M | −$49.2M |
| Dec 2020 | $1.83M | $28.3M | −$26.4M |
| Dec 2019 | $3.52M | $42.4M | −$38.9M |
| Dec 2018 | $4.99M | $46.8M | −$41.8M |
| Dec 2017 | $3.46M | $42.4M | −$38.9M |
| Dec 2016 | $5.92M | $64.9M | −$59.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.